sr141716 has been researched along with Edema, Pulmonary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feleder, C; Gertzberg, N; James, J; Johnson, A; MacDonald, H; Neumann, PH; Peng, J; Russo, V | 1 |
| Advenier, C; Chen, HZ; Cui, YY; D'Agostino, B; Finance, O; Marrocco, G; Naline, E; Rinaldi-Carmona, M; Risse, PA; Rossi, F; Zhang, Y | 1 |
2 other study(ies) available for sr141716 and Edema, Pulmonary
| Article | Year |
|---|---|
The intracerebroventricular injection of rimonabant inhibits systemic lipopolysaccharide-induced lung inflammation.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Injections, Intraventricular; Lipopolysaccharides; Lung; Male; Peroxidase; Piperidines; Pneumonia; Pulmonary Edema; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Signal Transduction; Time Factors; Toll-Like Receptor 4 | 2015 |
Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
Topics: Airway Obstruction; Animals; Benzoxazines; Bronchi; Bronchoconstriction; Camphanes; Cannabinoids; Capillary Permeability; Disease Models, Animal; Dose-Response Relationship, Drug; Esophagus; Extravasation of Diagnostic and Therapeutic Materials; Gastroesophageal Reflux; Guinea Pigs; Hydrochloric Acid; Male; Morpholines; Naphthalenes; Piperidines; Pulmonary Edema; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Respiratory Function Tests; Rimonabant; Trachea | 2007 |